• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future
Atrial fibrillation (AF) is now said to be at epidemic proportions.1 Although symptoms and heart failure are two of the main reasons that patients with AF suffer from reduced quality of life, thromboembolic complications, particularly stroke, remain the major determinant of significant morbidity and mortality.2 Importantly, the risk of thromboembolism (TE) is completely irrespective of symptoms, and hence the sad fact that people continue to present with catastrophic stroke in AF with no prior history of its detection.3 Appropriate anticoagulation is imperative to reduce the TE/stroke risk. Numerous large scale studies hav...
Source: Heart - February 18, 2013 Category: Cardiology Authors: Rajappan, K. Tags: Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Quantitative assessment of atrial conduit function: a new index of diastolic dysfunction
Conclusions Our study confirms that LACV contribution to stroke volume increases along with worsening DD, as assessed in the context of (near) constant-volume four-chamber heart physiology. Thus, LACV can serve as new parameter for DD grading severity in HF patients.
Source: Clinical Research in Cardiology - June 30, 2015 Category: Cardiology Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it�...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Atrial fibrillation for internists: current practice.
Abstract Atrial fibrillation (AF) has become a global epidemic and puts affected patients at high risk of adverse events. In this review we summarise the current evidence on risk factors and complications of AF, describe current treatment strategies, and outline new fields of research. Current evidence shows that hypertension and obesity are the two most important modifiable risk factors for the development of AF. Patients with AF face an increased stroke risk. Oral anticoagulation reduces this risk substantially. Mainly for reasons of safety and ease of use, non-vitamin K antagonist oral anticoagulants are prefer...
Source: Swiss Medical Weekly - March 8, 2020 Category: General Medicine Authors: Meyre P, Conen D, Osswald S, Kühne M, Meyer-Zürn C Tags: Swiss Med Wkly Source Type: research

Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century
Abstract: Background: Atrial fibrillation (AF) represents an increasing public health challenge with profound social and economic implications.Methods: A comprehensive synthesis and review of the AF literature was performed. Overall, key findings from 182 studies were used to describe the indicative scope and impact of AF from an individual to population perspective.Results: There are many pathways to AF including advancing age, cardiovascular disease and increased levels of obesity/metabolic disorders. The reported population prevalence of AF ranges from 2.3%–3.4% and historical trends reflect increased AF incidence. Es...
Source: International Journal of Cardiology - February 4, 2013 Category: Cardiology Authors: Jocasta Ball, Melinda J. Carrington, John J.V. McMurray, Simon Stewart Tags: Reviews Source Type: research

The role of diastolic filling in preserving left ventricular stroke volume — An MRI study
In this early part of the 21st century, many countries appear to be experiencing a ‘heart failure epidemic’, with prevalence rates worldwide in the order of 2% and increasing . But despite its significant global impact, there remains considerable debate over the most appropriate way to diagnose heart failure , especially that with a preserved ejection fraction (commonly known as HFPEF). HFPEF, defined as heart failure with a normal, or near normal, left ventricular ejection fraction (LVEF>50%), now comprises as much as 50–60% of those diagnosed with heart failure .
Source: International Journal of Cardiology - February 18, 2013 Category: Cardiology Authors: S. Offen, D. Celermajer, C. Semsarian, R. Puranik Tags: Letters to the Editor Source Type: research

The effect of continuous positive airway pressure therapy on vascular function in obstructive sleep apnea: how much is enough?
Over the last two decades, obstructive sleep apnea (OSA) has emerged as a considerable public health burden. Due to the ongoing epidemic of obesity, which is strongly linked to OSA, the prevalence of the disease has been steadily rising. According to recent data from the Wisconsin Sleep Cohort, the combination of sleep-disordered breathing as indicated by an apnea–hypopnea index of>5 events per hour and excessive daytime sleepiness occurs in approximately 14% of men and 5% of women between the ages of 30 and 70years . Cardiovascular diseases (CVDs) represent the principal morbidity and mortality in OSA and large-scale ep...
Source: Sleep Medicine - November 8, 2013 Category: Sleep Medicine Authors: Silke Ryan Tags: Editorials Source Type: research

Task shifting interventions for cardiovascular risk reduction in low-income and middle-income countries: a systematic review of randomised controlled trials
Conclusions There is a dearth of evidence on the implementation of task-shifting strategies to reduce the burden of CVD in LMICs. Effective task-shifting interventions targeted at reducing the global CVD epidemic in LMICs are urgently needed.
Source: BMJ Open - October 16, 2014 Category: Journals (General) Authors: Ogedegbe, G., Gyamfi, J., Plange-Rhule, J., Surkis, A., Rosenthal, D. M., Airhihenbuwa, C., Iwelunmor, J., Cooper, R. Tags: Open access, Cardiovascular medicine, Global health, Health services research Source Type: research

Endocannabinoids and cardiovascular prevention: real progress?
Authors: Nodari S, Manerba A, Metra M, Dei Cas L Abstract The prevalence of obesity continues to increase and represents one of the principal causes of cardiovascular morbidity and mortality. After the discovery of a specific receptor of the psychoactive principle of marijuana, the cannabinoid receptors and their endogenous ligands, several studies have demonstrated the role of this system in the control of food intake and energy balance and its overactivity in obesity. Recent studies with the CB1 receptor antagonist rimonabant have demonstrated favorable effects such as a reduction in body weight and waist circumf...
Source: Heart International - November 28, 2015 Category: Cardiology Tags: Heart Int Source Type: research

Nanocarriers as treatment modalities for hypertension.
Authors: Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J Abstract Hypertension, a worldwide epidemic at present, is not a disease in itself rather it is an important risk factor for serious cardiovascular disorders including myocardial infarction, stroke, heart failure, and peripheral artery disease. Though numerous drugs acting via different mechanism of action are available in the market as conventional formulations for the treatment of hypertension but they face substantial challenges regarding their bioavailability, dosing and associated adverse effects which greatly limit their therapeutic efficacies. Vari...
Source: Drug Delivery - February 8, 2017 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Impaired Activity of Ryanodine Receptors Contributes to Calcium Mishandling in Cardiomyocytes of Metabolic Syndrome Rats
Conclusion Principal findings of this work are that abnormal Ca2+ transient amplitude, contractile dysfunction; and impaired relaxation of MetS cardiomyocytes underlies intrinsic dysfunctional RyR2 and SERCA pump. Abnormal activity of RyRs was evidenced by its decreased ability to bind [3H]-ryanodine. Although the MetS condition does not modify RyR2 protein expression, its phosphorylation at Ser2814 is decreased, which impairs its capacity for activation during ECC. The dysfunctional RyRs, together with a decreased activity of SERCA pump due to decreased Thr17-PLN phosphorylation suggest a downregulation of CaMKII in MetS...
Source: Frontiers in Physiology - April 29, 2019 Category: Physiology Source Type: research

Atrial Fibrillation in Heart Failure —Diagnostic, Therapeutic, and Prognostic Relevance
AbstractPurpose of ReviewAtrial fibrillation (AF) and heart failure (HF) commonly coexist and are associated with an increased risk of hospitalization, morbidity, and mortality. Both conditions develop into epidemics due to the ageing of the population and lead to poorer prognosis for the individual patients. Therapeutic strategies include treatment with oral anticoagulation, and rate and rhythm control concepts to prevent stroke and improve the cardiovascular outcome.Recent FindingsEspecially in HF patients, data suggest that catheter ablation of AF is superior to medical treatment. In patients with both AF and HF undergo...
Source: Current Heart Failure Reports - May 28, 2019 Category: Cardiology Source Type: research

Abiomed Hits TCT 2019 Running with Compelling Data and New Approval
Abiomed certainly brought its A-game to the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference- being held now and throughout the weekend. The Danvers, MA-based company came armed with the news of a newly-approved device and data from its PROTECT III trial, an ongoing prospective, single-arm FDA post-market study for the Impella 2.5 and Impella CP in high-risk PCI. Abiomed, which was named one of the top 25 M&A targets in medtech, said an interim analysis of 898 patients from the PROTECT III trial demonstrated a reduction in the primary endpoint of death, stroke, myocardial infarction, and repeat pr...
Source: MDDI - September 26, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

How to Keep Alzheimer ’s From Bringing About the Zombie Apocalypse
I tried to kill my father for years. To be fair, I was following his wishes. He’d made it clear that when he no longer recognized me, when he could no longer talk, when the nurses started treating him like a toddler, he didn’t want to live any longer. My father was 58 years old when he was diagnosed with Alzheimer’s disease. He took the diagnosis with the self-deprecating humor he’d spent a lifetime cultivating, constantly cracking jokes about how he would one day turn into a zombie, a walking corpse. We had a good 10 years with him after the diagnosis. Eventually, his jokes came true. Seven years ...
Source: TIME: Health - November 20, 2019 Category: Consumer Health News Authors: Jay Newton-Small Tags: Uncategorized Alzheimer's Disease Source Type: news

Pages: 1  2